Our group is interested in the development of targeted and personalized therapies for patients with tumors of the lympho-hematopoietic system. We focus on characterization of oncogenic signaling networks in multiple myeloma and their underlying genetic aberrations in a combined functional and genetic approach Complementary to this, we develop T cell engaging therapies for cancer treatment in a variety of cancer entities. Our group translates the knowledge from preclinical research in these fields into the clinic and has initiated a broad early clinical trial program ranging from leukemia to prostate cancer. The program is supported by the central CCC MF Trial Office and is conducted in the Early Clinical Trials Unit (ECTU) of the CCC MF.